The Valuation Of Thoracic Radiotherapy In Extensive-stage Small Cell Lung Cancer

Objective: To estimate the difference between thoracic radiotherapycombined chemotherapy and chemotherapy alone in the treatment ofextensive-stage small cell lung cancer. The main aim was to evaluate thevaluation in the clinical treatment of extensive-stage small cell lung cancer.Materials and methods: Collect fifty-five patients treated in the1sthospital of Jilin University cancer center between June2010and December2012. They were diagnosed with extensive-stage small cell lung cancer.26patients received thoracic radiotherapy and chemotherapy(ChT/TRT),29patients received chemotherapy alone (ChT). All of them were accepted6cycles chemotherapy, the chemotherapy regimens consisted of either cisplatinand etoposide (EP) or carboplatin and etoposide (EC). The patients obtainedcomplete response to chemotherapy received total dose of40Gy at2.0Gy perfraction. The patients obtained partial response or stable disease tochemotherapy received total dose of54Gy at2.0Gy per fraction. One monthafter chemotherapy all patients get CR or PR began prophylactic cranialirradiation (PCI).Results: For the whole group, the follow-up time varied from one totwenty-four months, the median follow-up time was six months. The meanrecurrent time for ChT/TRT was8.50±5.90months, and the median recurrenttime was7.0months. As for the ChT, the mean recurrent time was5.35±2.89months, and the median recurrent time was5.0months. There was statisticaldifference between the recurrent time of the two groups, and the recurrent timeof ChT/TRT was longer. It means that the thoracic local control of ChT/TRTwas superior to ChT（Z=-1.992，P=0.048）. The median overall survival was 17.7months and14.4months, respectively. But there was no statisticaldifference between the two groups. The ChT/TRT was well tolerated, and nopatients was excluded due to serious complications.3patients suffered from2grade hematology toxicity, and3grade radiation pneumonitis was observed in2patients,5patients occurred2grade radiation esophagitis.Conclusion: The addition of thoracic radiotherapy to chemotherapyimproved the thoracic local control rates and prolonged the relapsed time ofpatients with extensive-stage small cell lung cancer. Furthermore, the toxicitiescaused by combined therapy were well tolerated.